Aveo Capital Partners LLC Acquires 171 Shares of Boston Scientific Co. (NYSE:BSX)

Aveo Capital Partners LLC grew its holdings in Boston Scientific Co. (NYSE:BSXFree Report) by 1.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,841 shares of the medical equipment provider’s stock after purchasing an additional 171 shares during the period. Aveo Capital Partners LLC’s holdings in Boston Scientific were worth $742,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of BSX. Louisiana State Employees Retirement System bought a new position in shares of Boston Scientific in the fourth quarter worth $5,116,000. Glenmede Trust Co. NA grew its holdings in Boston Scientific by 12.1% during the 3rd quarter. Glenmede Trust Co. NA now owns 10,442 shares of the medical equipment provider’s stock valued at $551,000 after buying an additional 1,123 shares in the last quarter. HealthInvest Partners AB bought a new stake in shares of Boston Scientific during the fourth quarter valued at about $3,746,000. Mackenzie Financial Corp lifted its holdings in shares of Boston Scientific by 65.1% in the fourth quarter. Mackenzie Financial Corp now owns 708,833 shares of the medical equipment provider’s stock worth $40,978,000 after buying an additional 279,513 shares in the last quarter. Finally, International Assets Investment Management LLC boosted its position in shares of Boston Scientific by 318.4% in the fourth quarter. International Assets Investment Management LLC now owns 89,031 shares of the medical equipment provider’s stock valued at $51,470,000 after acquiring an additional 67,753 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Trading Up 0.8 %

NYSE:BSX opened at $75.57 on Friday. The firm has a market capitalization of $110.87 billion, a P/E ratio of 63.50, a P/E/G ratio of 2.58 and a beta of 0.77. The company has a quick ratio of 1.14, a current ratio of 1.66 and a debt-to-equity ratio of 0.47. The company has a fifty day moving average of $71.38 and a 200 day moving average of $64.57. Boston Scientific Co. has a 52 week low of $48.35 and a 52 week high of $76.25.

Boston Scientific (NYSE:BSXGet Free Report) last issued its quarterly earnings data on Wednesday, April 24th. The medical equipment provider reported $0.56 EPS for the quarter, beating the consensus estimate of $0.51 by $0.05. The firm had revenue of $3.86 billion during the quarter, compared to the consensus estimate of $3.68 billion. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. On average, research analysts predict that Boston Scientific Co. will post 2.32 earnings per share for the current year.

Analyst Ratings Changes

BSX has been the topic of several recent analyst reports. Argus increased their target price on shares of Boston Scientific from $80.00 to $95.00 and gave the stock a “buy” rating in a research note on Tuesday, May 28th. Evercore ISI lifted their price objective on Boston Scientific from $72.00 to $78.00 and gave the company an “outperform” rating in a research note on Thursday, April 25th. Needham & Company LLC raised their price target on Boston Scientific from $71.00 to $82.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. UBS Group boosted their price objective on Boston Scientific from $74.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, April 25th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of Boston Scientific from $63.00 to $73.00 and gave the company a “hold” rating in a research note on Thursday, April 25th. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $76.70.

Get Our Latest Stock Analysis on BSX

Insiders Place Their Bets

In related news, EVP John Bradley Sorenson sold 17,587 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $71.50, for a total transaction of $1,257,470.50. Following the completion of the transaction, the executive vice president now owns 50,638 shares in the company, valued at $3,620,617. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Boston Scientific news, Director Charles J. Dockendorff sold 3,946 shares of the company’s stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $72.70, for a total transaction of $286,874.20. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP John Bradley Sorenson sold 17,587 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $71.50, for a total value of $1,257,470.50. Following the completion of the transaction, the executive vice president now owns 50,638 shares of the company’s stock, valued at approximately $3,620,617. The disclosure for this sale can be found here. In the last 90 days, insiders sold 74,644 shares of company stock worth $5,411,323. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Profile

(Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

See Also

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSXFree Report).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.